Aspect Biosystems is developing a proprietary 3D bioprinting and human cell culture technology platform capable of creating living human tissue models. After seeing about 90 percent of investigational drugs fail in clinical trials, the company’s initial products and services aim to improve the predictive accuracy of the pre-clinical drug discovery process by providing pharmaceutical companies and researchers with physiologically-relevant 3D human tissue models that they can employ in the development of novel therapeutics.
Aspect’s technology has the potential to drive a fundamental shift in the pharmaceutical industry by enabling the development of completely new therapeutics, enabling pharma to test drugs they may have shelved in the past due to a lack of appropriate models, and providing a platform with the potential to reduce the use of laboratory animals. Aspect has a long-term vision to expand beyond drug development, by creating human tissues on demand for broad applications in the life sciences including organ transplantation.
